Ki67 May Predict Benefit of Adjuvant Docetaxel in ER+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final 10-Year Results of the Breast International Group 2-98 Phase III Trial and the Role of Ki67 in Predicting Benefit of Adjuvant Docetaxel in Patients With Estrogen Receptor-Positive Breast Cancer
Eur. J. Cancer 2015 Jun 11;[EPub Ahead of Print], A Sonnenblick, PA Francis, HA Azim, E de Azambuja, B Nordenskjöld, J Gutiérez, E Quinaux, MG Mastropasqua, L Ameye, M Anderson, A Lluch, M Gnant, A Goldhirsch, A Di Leo, A Barnadas, H Cortes-Funes, M Piccart, J CrownFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.